logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10308655 B1

PDFFull Text
Date of Patent:
Jun. 04, 2019

Filed:

Dec. 23, 2015

Method of treating crohn's disease comprising a tlr2 antagonist

Applicant:

Ajou University Industry-academic Cooperation Foundation, Suwon-si, Gyeonggi-do, KR;

Inventors:

Sang Dun Choi, Suwon-si, KR;

Prasannavenkatesh Durai, Suwon-si, KR;

Asma Achek, Suwon-si, KR;

Assignee:

AJOU University Industry-Academic Cooperation Foundation, Suwon-si, Gyeonggi-do, KR;

Attorneys:

Vorys, Sater, Seymour and Pease LLP

Mih Suhn Koh

Primary Examiner:

Yong L Chu

Int. Cl.
CPC ...
C07D 487/04 (2006.01); A61P 1/00 (2006.01); A61P 27/02 (2006.01); A61P 1/02 (2006.01); A61P 7/00 (2006.01); A61P 19/06 (2006.01); A61P 25/28 (2006.01); A61P 11/06 (2006.01); A61P 31/12 (2006.01); A61P 17/00 (2006.01); A61P 19/02 (2006.01); A61P 37/08 (2006.01); A61P 13/12 (2006.01); A61P 27/16 (2006.01); A61P 11/00 (2006.01); A61P 29/00 (2006.01); A61P 1/04 (2006.01); A61P 27/00 (2006.01); C07C 251/24 (2006.01); C07D 207/277 (2006.01); C07D 211/26 (2006.01); C07D 211/34 (2006.01); C07D 243/08 (2006.01); C07D 265/30 (2006.01); C07D 333/78 (2006.01); C07D 401/06 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 409/12 (2006.01); C07D 471/04 (2006.01); C07D 471/10 (2006.01); A61K 9/00 (2006.01); A61K 31/5377 (2006.01); A61K 31/551 (2006.01); A61K 31/4178 (2006.01); A61K 31/4453 (2006.01); A61K 31/496 (2006.01); A61K 31/506 (2006.01);
U.S. Cl.
CPC ...
C07D 487/04 (2013.01); A61K 9/0053 (2013.01); A61K 31/4178 (2013.01); A61K 31/4453 (2013.01); A61K 31/496 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/551 (2013.01); A61P 1/00 (2018.01); A61P 1/02 (2018.01); A61P 1/04 (2018.01); A61P 7/00 (2018.01); A61P 11/00 (2018.01); A61P 11/06 (2018.01); A61P 13/12 (2018.01); A61P 17/00 (2018.01); A61P 19/02 (2018.01); A61P 19/06 (2018.01); A61P 25/28 (2018.01); A61P 27/00 (2018.01); A61P 27/02 (2018.01); A61P 27/16 (2018.01); A61P 29/00 (2018.01); A61P 31/12 (2018.01); A61P 37/08 (2018.01); C07C 251/24 (2013.01); C07D 207/277 (2013.01); C07D 211/26 (2013.01); C07D 211/34 (2013.01); C07D 243/08 (2013.01); C07D 265/30 (2013.01); C07D 333/78 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 409/12 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01);
Abstract

The present disclosure relates to a novel small molecule TLR2 antagonist, and particularly, to 19 novel TLR2 antagonists, a pharmaceutical composition, including the antagonists, for preventing or treating inflammatory diseases, and a TLR4 regulator. The novel TLR2 antagonists according to the present disclosure can be effectively used as a preparation for oral administration by having low molecular weight and high oral bioavailability, and can be useful in pharmaceutical compositions for preventing or treating inflammatory diseases since the secretion of IL-8 is effectively inhibited and in vivo cytotoxicity is not induced. In addition, the novel TLR2 antagonists according to the present disclosure can be used as a TLR4 regulator.

Find Patent Forward Citations

Loading…